We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Landmark Development Agreement Signed Between PDA and St. Petersburg State Chemical-Pharmaceutical Academy

By LabMedica International staff writers
Posted on 26 Jul 2012
The Parenteral Drug Association (PDA; Bethesda, MD, USA) and the Saint-Petersburg State Chemical-Pharmaceutical Academy (SPCPA; St. More...
Petersburg, Russia) have signed a memorandum of understanding to develop a Good Manufacturing Practices (GMP) and Regulatory Affairs Training Center in the area of pharmaceutical manufacturing, an important step in implementing higher standards of quality production in Russia by advancing its pharmaceutical manufacturing technology and quality control.

The Training Center, located in St. Petersburg, will carry out ongoing hands-on training programs for Russian GMP inspectors, SPCPA students, Russian pharmaceutical manufacturers, and professionals of the healthcare industry to improve knowledge and implementation of current GMP. The project will also facilitate the exchange of experience and information on relevant legislation and regulatory procedures. The knowledge gained by students during education in the St. Petersburg Academy will be used to conduct inspections of the pharmaceutical industry in Russia, as measures to help ensure a proper level of quality and efficiency of medical care to meet, as the primary priority, the interests of Russian and guest patients.

This timely project is supported by the government of St. Petersburg and the Ministry of Industry and Trade of the Russian Federation. Richard M. Johnson, PDA President said, "With 600+ pharmaceutical manufacturing plants in Russia it is clear that Russia has made it a priority to enhance understanding and implementing internationally consistent current GMPs. PDA considers this project critical to the overall health of the global pharmaceutical pipeline since there will be more and more of a push for international pharmaceutical companies to partner for manufacturing.” He added, “We are pleased that the SPCPA decided to choose PDA as their premier partner in this significant endeavor.”

Related Links:

Parenteral Drug Association
St. Petersburg State Chemical-Pharmaceutical Academy




Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.